Johnson & Johnson’s (JNJ) Dividend Growth Record Strengthens its Role in Dividend Paying Stocks

Core Insights - Johnson & Johnson (NYSE: JNJ) is recognized as one of the best dividend-paying stocks, with a strong dividend growth record and a market value nearing $425 billion [2][5]. Group 1: Financial Performance - In the second quarter, Johnson & Johnson reported a revenue increase of 5.8% year-over-year and an 18% rise in earnings [2]. - The company currently pays a quarterly dividend of $1.30 per share, resulting in a dividend yield of 2.95% as of September 19 [5]. Group 2: Business Structure - Until 2023, Johnson & Johnson had a robust consumer healthcare division, which included well-known products like Tylenol and Band-Aid, but this division has been spun off into a separate entity named Kenvue [3]. - Johnson & Johnson's diverse portfolio features immunology treatments such as Stelara and Tremfya, along with cancer medications like Darzalex and Erleada [4]. - The company is actively engaged in late-stage clinical trials, with 40 programs currently evaluating new drug candidates and seeking additional approvals for existing treatments [4].